@article{article, title  = {{Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2021}},

 month = {{12}},

 author = {{Stuart ASV and Shaw RH and Liu X and Greenland M and Aley PK and Andrews NJ and Cameron JC and Charlton S and Clutterbuck EA and Collins AM and Darton T et al}},

 doi = {{10.1016/s0140-6736(21)02718-5}},

 journal = {{The Lancet}},

 note = {{Accessed on 2024/09/19}}}